The study identified the 2.4 mg dose as optimal for combination development based on efficacy-tolerability balance
Several of the most promising peptides under investigation for psoriasis work specifically by modulating NF-kB activity
5FU adaptation alters mitochondrial activity Given the changes in mitochondrial abundance, without evident mitochondrial dysfunction (no cristae clearing, no change in apoptotic priming, no release of cytochrome c or mtDNA), we reasoned that the increase might be associated with increased functionality
These peptide therapies complement many of our existing programs, including hormone optimization, medical weight loss, longevity medicine, hair restoration, and skin rejuvenation
[8] One such potential pathway involves the activation of phospholipase C (PLC), which researchers suggest may lead to the release of inositol triphosphate (IP3) and diacylglycerol (DAG)